CIK 0001576885 · <br>Emerging growth company
Acumen Pharmaceuticals, Inc.
Sign in to watch- Ticker
- ABOS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 364108129
- Phone
- 617-344-4190
- Business address
- 1210-1220 WASHINGTON STREET, SUITE 210, NEWTON, MA, 02465
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-07-06 | Manning Paul B 10% owner | Conversion · Series A-1 Preferred Stock | −1,634,515 | 0 | ||
| 2021-07-06 | Manning Paul B 10% owner | Conversion · Series B Preferred Stock | −1,315,969 | 0 | ||
| 2021-07-06 | Manning Paul B 10% owner | Conversion · Series B Preferred Stock | −657,985 | 0 | ||
| 2021-07-06 | Zuga Matt Chief Financial Officer | Conversion | +26,187 | 26,187 | ||
| 2021-07-06 | Zuga Matt Chief Financial Officer | Conversion · Series A-1 Preferred Stock | −15,659 | 15,659 | ||
| 2021-07-06 | Zuga Matt Chief Financial Officer | Conversion · Series B Preferred Stock | −10,528 | 10,528 | ||
| 2021-07-06 | Stalfort John A III Director | Conversion | +130,180 | 137,324 | ||
| 2021-07-06 | Stalfort John A III Director | Purchase | +35,000 | $16.00 | $560K | 172,324 |
| 2021-07-06 | Stalfort John A III Director | Conversion | +131,595 | 131,595 | ||
| 2021-07-06 | Stalfort John A III Director | Conversion · Series A-1 Preferred | −130,180 | 0 | ||
| 2021-07-06 | Stalfort John A III Director | Conversion · Series B Preferred | −131,595 | 0 | ||
| 2021-07-06 | OConnell Daniel Joseph President and CEO | Conversion | +123 | 1,542 | ||
| 2021-07-06 | OConnell Daniel Joseph President and CEO | Option exercise | +35 | $4.47 | $156 | 1,577 |
| 2021-07-06 | OConnell Daniel Joseph President and CEO | Shares withheld for taxes | −10 | $16.00 | $160 | 1,567 |
| 2021-07-06 | OConnell Daniel Joseph President and CEO | Conversion · Series A Preferred Stock | −123 | 0 | ||
| 2021-07-06 | OConnell Daniel Joseph President and CEO | Option exercise · Warrant (Right to Buy) | −35 | 0 | ||
| 2021-07-06 | Hardie Robert D. 10% owner | Conversion | +2,950,484 | 3,040,193 | ||
| 2021-07-06 | Hardie Robert D. 10% owner | Purchase | +312,500 | $16.00 | $5.0M | 3,352,693 |
| 2021-07-06 | Hardie Robert D. 10% owner | Conversion | +657,985 | 657,985 | ||
| 2021-07-06 | Hardie Robert D. 10% owner | Conversion · Series A-1 Preferred Stock | −1,634,515 | 0 |
Page 11 of 13 · 246 trades